ArticlePediatric cardiology2026
Transplantation for Congenital Heart Disease in Children-A Quest to Do Better.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children with congenital heart disease (CHD) represent the largest group of pediatric heart transplant recipients but experience lower graft survival than those transplanted for cardiomyopathy. We evaluated post-transplant outcomes among CHD recipients at the Hospital for Sick Children (HSC) and identified predictors of graft loss. Pediatric patients (< 17 years) undergoing heart transplantation for CHD between 1993 and 2023 were analyzed using the Pediatric Heart Transplant Society registry. Outcomes of CHD recipients at HSC (CHD HSC) were compared with cardiomyopathy HSC recipients, CHD recipients at other centers (CHD Non-HSC), and a propensity score-matched (PSM) cohort adjusting for pre- and peri-transplant risk factors. Kaplan-Meier survival and multivariable Cox proportional hazards analyses were performed. Among 4,362 pediatric CHD transplant recipients, 152 underwent transplantation at HSC. Freedom from graft loss for CHD HSC at 5, 10, and 15 years was 71.8%, 63.0%, and 58.4%, lower than in Cardiomyopathy HSC recipients (p < 0.0001), but similar to CHD Non-HSC (p = 0.6043). Survival remained comparable in the PSM cohort (n = 140, p = 0.4599). Conditional survival beyond 1 year was similar between groups, suggesting early mortality drives differences. CHD HSC recipients demonstrated longer freedom from CAV (p = 0.0041) and infection (p = 0.0335). Predictors of graft loss included pre-transplant ECMO (HR 3.11), ICU admission (HR 2.39), PRA > 10% (HR 2.49), African American/Black race/ethnicity (HR 2.71), and longer waitlist duration (HR 1.06). Graft survival in CHD recipients at HSC remains lower than in cardiomyopathy recipients but comparable internationally. Optimizing pre-transplant care, sensitization management, and equity-focused interventions may enhance outcomes.
Indexed as
Identifiers
42886358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.